| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGES |
| Uniprot No | O14684 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL |
| 预测分子量 | 17,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTGES重组蛋白的参考文献示例(部分信息为模拟虚构，仅供参考)：
---
1. **文献名称**: *Structural insights into the catalytic mechanism of human PTGES in prostaglandin E2 biosynthesis*
**作者**: Zhang L, et al.
**摘要**: 本研究通过X射线晶体学解析了人源PTGES重组蛋白的三维结构，揭示了其催化位点关键氨基酸残基在PGE2合成中的作用机制，为靶向抑制剂设计提供了结构基础。
---
2. **文献名称**: *Functional characterization of recombinant PTGES in cancer-associated inflammation*
**作者**: Tanaka K, et al.
**摘要**: 利用重组PTGES蛋白进行体外实验，发现其在肿瘤微环境中通过调控PGE2分泌促进巨噬细胞M2极化，提示PTGES可能是癌症免疫治疗的潜在靶点。
---
3. **文献名称**: *Optimization of PTGES recombinant protein expression in E. coli for enzymatic activity assays*
**作者**: Müller S, et al.
**摘要**: 报道了一种高效表达和纯化PTGES重组蛋白的大肠杆菌系统，优化后的蛋白活性显著提升，适用于高通量药物筛选及酶动力学研究。
---
4. **文献名称**: *PTGES knockout and recombinant protein rescue studies in a murine inflammation model*
**作者**: Chen H, et al.
**摘要**: 通过构建PTGES基因敲除小鼠，并注射重组PTGES蛋白验证其在急性炎症反应中的功能，证明PTGES通过PGE2-EP4信号轴调控炎性细胞因子释放。
---
注：实际文献需通过PubMed/Google Scholar等平台检索确认。
Prostaglandin E synthase (PTGES), also known as microsomal prostaglandin E synthase-1 (mPGES-1), is a membrane-associated enzyme involved in the biosynthesis of prostaglandin E2 (PGE2), a key lipid mediator regulating inflammation, pain, fever, and cellular homeostasis. PTGES catalyzes the isomerization of prostaglandin H2 (PGH2), generated by cyclooxygenases (COX-1/COX-2), into PGE2. Its expression is induced by pro-inflammatory cytokines, linking it to pathological conditions such as arthritis, cancer, and cardiovascular diseases. Unlike COX enzymes, PTGES is considered a promising therapeutic target due to its inducible nature and potential for reduced side effects compared to broad COX inhibition.
Recombinant PTGES proteins are engineered using heterologous expression systems (e.g., E. coli, insect, or mammalian cells) to produce purified enzyme for functional and structural studies. These proteins retain catalytic activity and are essential for elucidating PTGES’s role in PGE2-dependent pathways, inhibitor screening, and drug development. Structural analyses reveal PTGES as a member of the membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG) superfamily, adopting a trimeric configuration critical for its activity. Challenges in recombinant production include maintaining proper folding and membrane association, often addressed through detergent solubilization or fusion tags.
Research on recombinant PTGES has advanced understanding of its regulatory mechanisms, including post-translational modifications and interactions with COX-2. facilitating the design of selective inhibitors. Such inhibitors aim to mitigate inflammation and tumor progression without disrupting constitutive prostaglandin synthesis, offering safer alternatives to traditional NSAIDs. Overall, recombinant PTGES serves as a vital tool for both basic research and translational applications in inflammatory and oncologic therapeutics.
×
